Clinical Report: Recurrence of Felty Syndrome Triggered by Immunotherapy

Overview

This report details a case of Felty syndrome recurrence in a 71-year-old man with metastatic melanoma following immunotherapy. The patient experienced severe neutropenia after receiving nivolumab and relatlimab, highlighting the risks of immune-related adverse events in patients with pre-existing autoimmune conditions.

Background

Immune checkpoint inhibitors (ICIs) are essential in treating advanced melanoma but can exacerbate pre-existing autoimmune diseases. Felty syndrome, a rare complication of rheumatoid arthritis characterized by neutropenia and splenomegaly, poses significant risks, including increased mortality from infections. Understanding the interplay between ICIs and autoimmune conditions is crucial for optimizing patient management and outcomes.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• Felty syndrome can recur in patients with a history of rheumatoid arthritis after ICI treatment.
• The patient experienced a neutrophil count drop to 0.0 cells/µL following immunotherapy.
• Rapid recovery of neutrophil counts was achieved with intravenous methylprednisolone and methotrexate.
• Close monitoring and early intervention are critical in managing irAEs in patients with autoimmune conditions.
• Combination immunotherapy was chosen over ipilimumab due to a lower risk of high-grade irAEs.

Clinical Implications

Healthcare providers should be vigilant in monitoring patients with autoimmune diseases undergoing ICI therapy for signs of disease recurrence or exacerbation. Early identification and prompt treatment of complications like neutropenia are essential to prevent severe outcomes.

Conclusion

This case underscores the need for careful consideration of ICI-induced adverse events in patients with pre-existing autoimmune conditions, emphasizing the importance of collaborative care in managing these complex cases.

References

1. The ASCO Post, 2018 -- Activity of T Cells in Metastatic Melanoma Resistant to Immune Checkpoint Inhibitor Treatment
2. The ASCO Post, 2015 -- PET/CT Detects Asymptomatic Melanoma Recurrences Related Articles
3. NCCN GUIDELINES® INSIGHTS, 2024 -- Melanoma: Cutaneous
4. Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy - PubMed
5. Felty’s syndrome - PMC
6. The ASCO Post — Activity of T Cells in Metastatic Melanoma Resistant to Immune Checkpoint Inhibitor Treatment
7. Blood Cancer Journal — Case Series of Indolent Nodal T Follicular Helper Cell Lymphomas
8. CE NCCN GUIDELINES® INSIGHTS Melanoma: Cutaneous,
9. Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy - PubMed
10. Felty’s syndrome - PMC